Гены системы воспаления как факторы риска инфаркта миокарда и маркеры его прогноза
Диссертация
В основе развития острого коронарного синдрома (ОКС) и ИМ лежит процесс дестабилизации атеросклеротической бляшки, который можно отнести к классической воспалительной реакции, в которой непосредственное участие принимают эндотелиальные клетки, макрофаги, Т-лимфоциты, нейтрофилы и гладкомышечные клетки. Мы посчитали важным оценить влияние генов, белковые продукты которых участвуют… Читать ещё >
Список литературы
- Heart and Stroke Statistical Update. American Heart Association 2002.
- Cambien F, Poirier O, Lecerf L et al. Deletion polymorfhism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992−359:641−644.
- Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005- 111: 3481−3488.
- Libbly P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation. 2001−104:365−372.
- Goldstein JL, BrownMS. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am. 1982−66:335−362.
- Seidman CE, Seidman JG. Hypertrophic cardiomyopathy. In: Scriver CR, BeaudetAL, Sly WS et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill-'2001:5433−5450.
- Lombardi R, Betocchi S. Aetiology and pathogenesis of hypertrophic cardiomyopathy. Acta Paediatr Suppl. 2002−91:10−14.
- Lifiton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001−104:545−556.
- Luft FC. Mendelian forms of human hypertension and mechanisms of disease. Clinical Medicine & Research. 2003−1:291−300.
- Lemmens R, Abboud S, Robberecht W, Vanhees L, Pandolfo M, Thijs V, Goris A. Variant on 9p21 strongly associates with coronary heart disease, but lacks association with common stroke. Eur J Hum Genet. 2009 Mar 25. Epub ahead of print. <>
- Samani NJ, Erdmann J, Hall AS et al WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007−357:443−53. Epub 2007 Jul 18.
- McPherson R, Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease. Science (Wash DC) 2007−316:1488−1491.
- Helgadottir A, Thorleifsson G, Manolescu A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007- 8−316(5830): 1491−3. Epub 2007 May 3.
- Samani NJ. Large scale association analysis of novel genetic loci for coronary artery disease. Arteriosclerosis, thrombosis and vascular biology. 2009−29:774−780.
- Wang Q. Molecular genetics of coronary artery disease. Curr Opin Cardiol. 2005−20:182−188.
- O’Donnell CJ, Cupples LA, D’Agostino RB et al. Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s. Framingham Heart Study. BMC Med.Genet. 2007−8 Suppl 1: S4.
- Ashley EA, Butte AJ, Wheeler-MT et al. Clinical assessment incorporating a. personal genome. Lancet 2010−375(9725): 1525−35.
- Tobin MD, Braund PS, Burton PR et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 2004−25:459−467.
- Yamada Y, Izawa H, Ichichara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002−347:1916−1923.
- Ozaki, К.- Ohnishi, Y.- Iida, A. et, al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nature Genet. 2002−32:650−654, Note: Erratum: Nature Genet. 2003−33: 107 only.
- Anand SS, Xie C, Pare G et al. Genetic Variants Associated With Myocardial Infarction Risk Factors in Over 8000 Individuals From Five Ethnic Groups. The INTERHEART Genetics Study Circ Cardiovasc Genet. 2009−2:16−25.
- Archacki SR, Angheloiu G, Tian XL et al. Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiol Genomics. 2003−15(.l):65−74.
- Данковцева E.H., Затейщиков Д. А., Чудакова Д.А и соавторы. Ассоциация генов факторов гемостаза с ранним развитием ишемической болезни сердца и манифестацией инфаркта миокарда в молодом возрасте. Кардиология. 2005−45:17−24.
- Чистяков* Д.А., Кобалава Ж. Д., Терещенко С. Н. Полиморфизм гена сосудистого рецептора ангиотензина II при сердечно-сосудистых заболеваниях. Терапевтический архив. 2000−76:30.
- Шевцов С.П., Кучинский А. П., Дзеранова Н.Я и соавторы. Анализ полиморфизмов1 аполипопротеиновых генов ароВ и ароСЗ у пациентов с инфарктом миокарда. Молекулярная генетика, микробиология и> вирусология, 1994-(3):33−6.
- Voevoda MI, Ustinov SN, Yudin NS et al. Association of the CCR2 chemokine receptor gene polymorphism with myocardial infarction. Dokl Biol Sci. 2002−385:367−70.
- Сергеева Т.В., Чистяков Д. А., Кобалава Ж. Д., Моисеев B.C. Полиморфизм генов каталазы и глутатионпероксидазы и макроангиопатия у пациентов с инсулиннезависимым диабетом и гипертензией. Генетика, 2001 -3 7(3):418−21.
- Сироткина О.В., Заботина A.M., Беркович О. А. и соавторы. ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ АДФ-РЕЦЕПТОРА ТРОМБОЦИТОВ P2Y12, АССОЦИИРОВАННЫЕ С ИЗМЕНЕНИЕМ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ ТРОМБОЦИТОВ И РАЗВИТИЕМ СЕРДЕЧНОСОСУДИСТЫХ ЗАБОЛЕВАНИЙ. Генетика. 2009−45:247−253.
- Чудакова Д.А., Минушкина Л. О., Затейщиков Д. А. Изучение полиморфизма маркера G(-455)A гена FGb с ИБС. Генетика. 2004−40:1406.
- Кузьмина А.А., Латфулин И. А. Гаплотипы HLA у молодых пациентов с инфарктом миокарда. Терапевтические архивы, 1998−70(8):33−7.
- Пчелина C.H., Сироткина O.B., Шейдина A.M и соавторы. Генетические факторы риска развития инфаркта миокарда у мужчин молодого возраста, проживающих в северо-западном регионе России. Кардиология. 2007−47:29−34.
- Малыгина Н.А., Костомарова И. В., Мелентьев А. С. Связь I/D-полиморфизма гена ангиотензин превращающего фермента с наследственной предрасположенностью кинфаркту миокарда. Клиническая медицина. 2002−8:25.
- Шагисултанова Е.И., Мустафина О. Е., Туктарова И".А., Хуснутдинова Е. И. Полиморфизм Hindlll гена липопротеиновой липазы и риск инфаркта миокарда. Молекулярная генетика, микробиология и вирусология, 2001-(3): 18−22.
- Шейдина A.M., Пчелина С. Н., Демидова Д.М и соавторы. Анализ частот аллелей четырех однонуклеотидных полиморфизмов в 5'-нетранслируемой1 81области гена АВСА1 у молодых мужчин с инфарктом миокарда. Кардиология, 2004−44(8):40−5.
- Попова Л.В., Николаев К. Ю., Николаева A.A., Воронина Е. Г. Особенности клинического течения инфаркта1 миокарда при полиморфизмах гена эндотелиальной NO-синтазы. Клиническая медицина. 2008−86:32−35.
- Чудакова Д.А., Минушкина JI.O., Затейщиков Д. А., Носиков В. В. Ассоциация полиморфного маркера А1/А2 гена ITGB3 с сердечнососудистыми заболеваниями и инфарктом миокарда. Генетика. 2004−40:1402−1405.
- Шахнович P.M., Ноева Е. А., Руда М.Я. IfD полиморфизм гена ангиотензин-превращающего фермента* (АПФ) у больных с различными формами ИБС. Всероссийская конференция «Достижения молекулярной медицины и генетики в кардиологии» 1999. Тезисы докладов.
- Терещенко С.Н., Демидова И. В., Кобалава' Ж.Д. Полиморфизм гена АПФ, структурно-функциональное состояние левого желудочка у больных постинфарктной ¦ сердечной недостаточностью и эффекты ингибитора АПФ периндоприла. Терапевтический архив. 2002−4:56.
- Беркович O.A., Баженова Е. А., Волкова Е.А и соавторы. I/D-полиморфизм гена ангиотензин превращающего фермента у мужчин с инфарктом миокарда в молодом возрасте. Российский физиологический журнал им. Сеченова, 2001−87:642−648.
- Чистяков Д.А., Демуров Л. М., Кондратьев Я. Ю. Полиморфизм гена ангиотензин превращающего фермента при артериальной гипертонии и сердечно- сосудистых заболеваниях в московской популяции. Молекулярная биология. 1998 Т. 32. № 3. С. 410.
- Гукова С.П., Фомичева Е. В., Ковалев Ю. П. Роль структурного полиморфизма ангиотензин превращающего фермента в развитии инфаркта миокарда. Клиническая медицина, 1997−75(9):36−9.
- Мустафина О.Е., Шагисултанова Е. И., Туктарова И. А., Хуснутдинова Е. К. Полиморфизм гена аполипопротеина Е и риск инфаркта миокарда. Молекулярная биология, 2002−36(6):978−84
- Tereshchenko IP, Petrkova J, Mrazek F et al. The macrophage migration inhibitory factor (MIF) gene polymorphism in Czech and Russian patients with myocardial infarction. Clin Chim Acta. 2009−402(l-2): 199−202. Epub 2009 Jan 9.
- Fuster, V, Moreno, PR, Fayad, ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005−46:937.
- Falk, E, Shah, PK, Fuster, V. Coronary plaque disruption. Circulation 1995- 92:657.
- Ambrose, JA, Tannenbaum, MA, Alexopoulos, D, et al. Angiographic progression of coronary artery disease in the development of myocardial infarction. J Am Coll Cardiol 1988−12:56.
- Little, WC, Constantinescu, M, Applegate, RJ, et al. Can coronary angiography predict the siteof a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988−78:1157.
- Giroud, D, Li, JM, Urban, P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992−69:729.к
- Glaser, R, Selzer, F, Faxon, DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005- 111:143.
- Waxman S., Ishibashi F, Muller J.E. Detection and Treatment of Vulnerable Plaques and Vulnerable Patients. Circulation. 2006- 114:2390−2411
- Панченко Е.П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. Москва, 1999.
- Virmani R, Kolodgie FD, Burke АР, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vase Biol. 2000−20:1262−1275.
- Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996−93:1354−1363.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005−352:1685−1695.
- Duff GW, Libby P, Ordovas JM, Reilly PR The future of living well to 100. Am J Clin Nutr. 2006−83:488S-490S.
- Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol 2002−14:123−128.62. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002−20:197−216.
- Libby P. Molecular basic of the acute coronary syndrome. Circulation 1995- 91:2844−2850.
- Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor
- Caligiuri G, Rudling M, Ollivier V, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003−9:10−17.
- Robertson AKL, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003−112:1342−1350.
- Карпов Ю.А. Воспаление и атеросклероз: состояние проблемы и нерешенные вопросы. Сердце 2003−2(4): 190−192.
- Floyd-Smith, G. A.- Whitehead, A. S.- Colten, Н. R.- Francke, U. Human С-reactive protein gene (CRP) is located on the proximal long arm of chromosome 1. Cytogenet. Cell Genet. 1985−40: 630 only.
- Floyd-Smith, G. A.- Whitehead, A. S.- Colten, H. R.- Francke, U.: The human C-reactive protein gene (CRP) and serum amyloid P component gene (APCS) are* located on the proximal long arm of chromosome 1-. Immunogenetics 1986−24:171−176.
- Walsh, M.-T.- Divane, A.- Whitehead, A. S.: Fine mapping of the human pentraxin gene region on chromosome lq23. Immunogenetics 1996−44: 62−69.
- Goldman, N. D.- Liu, Т.- Lei, K.-J.: Structural analysis of the locus containing the human C-reactive protein gene and its related pseudogene. J. Biol. Chem. 1987−262:7001−7005.
- Kushner I, Rzewnicki D, Samols’D. What does minor elevation of C-reactive protein signify? Am. J. Med 2006- 119:166,e 17−28.
- Pearson Т., Mensah G., Meinertz T. et al. Markers of inflammation and cardiovascular disease application to clinica and public health practice. A statement
- Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996−144(6):537−47.
- Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004 Dec 16−351(25):2599−610.
- Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002−252(4):283−94. Review.
- Volanakis J.E. Human C-reactive protein: expression, structure and function. Mol. Immunol 2001−38:189−97.
- Majello B, Arcone R, Toniatti C, Ciliberto G. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J. 1990−9(2):457−65.
- Zwaka, TP, Hombach, V, Torzewski, J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001−103:1194.
- Verma, S, Wang, CH, Li, SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002−106:913.
- Pasceri, V, Willerson, JT, Yeh, ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000- 102:2165.
- Pasceri, V, Chang, J, Willerson, JT," Yeh, ET. Modulation of C-reactive proteinmediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001- 103:2531.
- Zacho, J, Tybjaerg-Hansen, A, Jensen, JS, et al. Genetically elevated’C-reactive protein and ischemic vascular disease. N Engl J Med 2008−359:1897.
- Clapp, BR, Hirschfield, GM, Stony, C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005−111:1530.
- Paffen, E, Vos, HL, Bertina, RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vase Biol 2004- 24:975.
- Taylor, KE, Giddings, JC, van den, Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vase Biol 2005−25:1225.
- Pepys, MB, Hawkins, PN, Kahan, MC, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005−97:e97.
- Ridker, PM, Cushman, M, Stampfer, MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in
- Ridker, PM, Glynn, RJ, Hennekens, CH. C-reactive protein-adds to the predictive value of total and HDL cholesterol in determining risk offirst myocardial infarction. Circulation 1998−97:2007.
- Cannon C, Morrow D, Jesse R et al. National Academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007−115: e356-e375.
- Brull D J, Serrano N, Zito F et.al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vase Biol 2003−23:2063−2069.
- Kathiresan S., MD- Larson M., Vasan R. et al. Contribution of clinical correlation and 13 C-reactive protein, gene polymorphisms to interindividual variability in serum C-reactive protein level: Circulation. 2006- 113:1415−1423.
- Hage F., Szalai A. C-reactive protein gene polymorphisms, G-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007−50:1115−1122.
- Lange LA, Carlson CS, Hindorff LA, et al. Association of polymorphismsin the CRP gene with- circulation C-reactive protein levels and cardiovascular events. JAMA 2006−296:2703−11. /
- Crawford DC, Sanders CL, Qin X, et al. Genetic variation is associated with C-reactive protein levels in the third National Health and Nutrition Examination Survey. Circulation 2006−114:2458−2465. >
- Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990−8:253−278.
- Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998−128:127−137.
- Koenig W- Khuseyinova N. Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007−27:15.
- Seino Y, Ikeda U, Ikeda M et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994- 6: 87−91.
- Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996- 127: 263 271.
- Maier W, Altwegg LA, Corti R et al. Inflammatory markers at the site of ruptured plaque in acute myocardial, infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005- 111: 13 551 361
- Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in. patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc. 2001−286:2107−2113.
- Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma-concentration of interleukin-6 and’the risk of future myocardial^infarction among apparently healthy men. Circulation. 2000−101:1767−1772.
- Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. J Am Med Assoc. 2002−288:980−987.
- Ferguson-Smith, A. C.- Chen, Y.-F.- Newman, M. S. et al. Regional localization of the interferon beta-2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human5chromosome 7pl5-p21. Genomics 1988−2:203−208.
- Chen, Y.- Ferguson-Smith, A. C.- Newman, M. S. et al* Regional localization’of the human beta 2-interferon gene. Am. J. Hum. Genet. 1987−41: A161.
- Bowcock, A. M.- Kidd, J. R.- Lathrop, G. M. et al. The human 'interferon-beta-2/hepatocyte stimulating factor/interleukin-6' gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 1988−3:8−16.
- Akira S, Isshiki H, Nakajima T et al. Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. Ciba Found Symp. 1992−167:47−62- discussion 62−7. Review.
- Kristiansen OP, Nols0e RL, Larsen L et al. Association of a functional 17beta-estradiol sensitive IL6−174G/C promoter polymorphism with early-onset type 1 diabetes in females. Hum Mol Genet. 2003−12(10): 1101−10.
- Lalouschek W, Schillinger M, Hsieh K et al. Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events. Clin Chem Lab Med. 2006−44(8):918−23.
- Sie MP, Sayed-Tabatabaei FA, Oei HH et al. Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study
- Humphries SE, Luong LA, Ogg MS et al. The interleukin-6 -1740G promoter polymorphism is associated with risk of coronary artery disease and systolic blood pressure in healthy men. Eur Heart J. 2001−22:2243−2252.
- Georges JL, Loukaci V, Poirier O et al. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de F Infarctus du Myocarde. J Mol Med. 2001−79(5−6):300−5.
- Chiappelli M, Tampieri C, Tumini E et al. Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet. 2005−32(6):349−53.
- Antonicelli R, Olivieri F, Bonafe M et al. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005−103(3):266−71.
- Manginas A, Tsiavou A, Chaidaroglou A et al. Inflammatory cytokine gene variants in coronary artery disease patient in Greece. Coron Artery Dis. 2008−19(8):575−82.
- Basso F- Gordon D.O. Lowe-' Rumley A et al. Interleukin-6 -174G>C Polymorphism and Risk of Coronary Heart Disease in West of Scotland Coronary Prevention Study (WOSCOPS) Arteriosclerosis, Thrombosis, and Vascular Biology. 2002−22:599.
- Lieb W, Pavlik R, Erdmann J et al. No association of interleukin-6 gene polymorphism (-174 GC) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol. 2004−97(2):205−12.
- Azzawi M, Hasleton P. Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease. Cardiovasc Res 1999−43:850−9.
- Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovascular Research 2008- 79(3):360−376.
- Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002−87:107−112 doi:10.1136/heart.87.2.107
- Pennica, D.- Nedwin, G. E.- Hayflick, J. S. et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984−312: 724 729.
- Verstrepen L, Bekaert T, Chau TL et al. TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci. 2008−65(19):2964−2978. Review. > t .
- Vila-del Sol V, Punzon C, Fresno M. IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. J Immunol. 2008- 181(7):4461−4470.
- Knight JC, Kwiatkowski D. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Physicians. 1999- 111(4):290−298. Review.
- Bernard V, Pillois X, Dubus I et al. The -308 GA tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med. 2003−41(4):511−6.
- Herrmann SM, Ricard S, Nicaud V et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest. 1998−28(l):59−66.
- Padovani JC, Pazin-Filho A, Simoes MV, et al. Gene polymorphisms in the TNF locus and the risk of myocardial infarction. Thromb Res 2000−100:263−269.
- Appoloni O, Duront E, Vandercruys M et al- Association between the TNF-2 allele and a better survival- in cardiogenic shock. Chest 2004- 125:198 011 982.
- Roch W, Tiroch K, von Beckerath N et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms- and restenosis after coronary artery stenting. Cytokine. 2003.21 -24(4): 161 -171.
- Schreyer, S. A., Vick, С. M. and LeBoeuf, R. C. Loss of lymphotoxin-a but not tumor necrosis factor reduces atherosclerosis in: mice- Ji Biol-. Chem: 2002−277:12 364−12 368.
- Ozaki, K., Inoue, K., Sato, H. et al. Functional^^ variationin LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-a secretion in vitro. Nature 2004- 429: 72−75.
- Jongeneel, C. V.- Briant, L.- Udalova, I. A. et al. Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc. Nat. Acad. Sci. 1991−88:9717−9721.
- Mizuno H, Sato H, SakataY et al. Impact of atherosclerosis-related gene polymorphisms on mortality and recurrent events after myocardial* infarction. Atherosclerosis. 2006−185:400−5. Epub 2005 Jul 28.
- Yamada A, Ichihara S, Murase Y et al. Lack of association of polymorphisms of the lymphotoxin alpha gene with myocardial infarction in Japanese. J Mol Med. 2004 Jul-82(7):477−83. Epub 2004 Jun 3.
- Koch W, Hoppmann P, Michou E et al. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. Hum Mol Genet .2007 Aug 1- 16(15):1821−7. Epub 2007 May 21.
- Clarke R, Xu P, Bennett D et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS-case-control study. PLoS Genet.2006−2(7):el07.
- Sedlacek K, Neureuther K, Mueller JC et al. Lymphotoxin-alpha and galectin-2 SNPs are not associated with myocardial infarction in two different German populations. Mol Med 2007−85:997−1004. Epub 2007 May 12.
- Asselbergs FW, Pai JK, Rexrode KM et al. Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk coronary heart disease. Clin Sci (Lond) 2007- 112:291−8.
- Blobe GC, Schiemann WP, Lodish.HF. Role of transforming growth factor beta in human disease. N Engl J Med2000−342:1350−7.
- Bujak M, Frangogiannis NG. The role of TGF-0 signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007−74(2):184−195.
- Annes JP, Mungers JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003−116:217−224.
- Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986−261:4337−4345.
- Werner F, Jain MK, Feinberg MW et al. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem 2000−275:36 653−36 658.
- Ikeuchi M, Tsutsui H, Shiomi T et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004−64:526−535.
- Okada H, Takemura G, Kosai K et al. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuated left ventricular remodeling and heart failure. Circulation 2005- 111:24 302 437.
- Liao R. Yin and Yang of myocardial’transforming growth factor-betal: timing is everything. Circulation 2005- 111:2416−2417.
- Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation, of transforming growth factor-13 is inhibited in transgenic apolipoprotein (a) mice. Nature 1994−370:460−462.
- Schiller M., Javelaud D., Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004−35:83−92.
- Cambien F, Ricard S, Troesch A, et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial’infarction and blood pressure. The etude cas-temoin de l’infarctus du myocarde (ECTIM) study. Hypertension 1996−28:881−7
- Yokota M, Ichihara S, Lin TL, et al. Association of a T29-C polymorphism of the transforming growth factor-betal gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000−101:2783−7.
- Crobu F, Palumbo L, Franco E et al. Role of TGF-beta 1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMS Med Genet 2008−29:9−13.
- Sie MP, Uitterlinden AG, Bos MJ et al. TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke 2006−37(11):2667−71. Epub 2006 Oct 5.
- Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004- 16(11): 1201−1210.
- Samson M., Soularue P., Vassart G., Parmentier M. Genomics 1996−36:522−526.
- Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med. 1998−338:436−444.
- Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med 1996−2:1174−1
- Potteaux S- Combadiere C- Esposito B et al. Role of. Bone Marrow-Derived CC-Chemokine Receptor 5 in the Development of Atherosclerosis of Low-Density Lipoprotein Receptor Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006−26:1858
- Kuziel WA, Dawson TS, Quinones M et al. CCR5 deficiency not protective in the early stages of atherogenesis in ApoE knockout mice. Atherosclerosis 2003−167:25−32.
- Szalai S, Duba J, Prohaszka Z et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Atherosclerosis 2001−158:233−239.
- Pai JK, Kraft P, Cannuscio CC et al. Polymorphisms in the CC-chemokine receptor -2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006−186:132−139.
- Balistreri CR, Candore C, Caruso M et al. Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica. 2008 -93 (4):63 7−63 8.
- Gonzalez P, Alvarez R, Batalla A et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immunity 2001- 2:191−195.
- Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning, Ed. Nolan, C. Cold Spring Harbor, N.Y.: Cold Spring Harbor Lab. Press. 1989.
- He B., Navikas V., Lundah, J. et al. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol, 1995−63:143−147.
- Roth MP, Nogueira L, Coppin H. et al. Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA. J Neuroimmunol. 1994−51:93−99.
- Sandford A.J., Pare P.D. Direct PCR of small genomic DNA fragments from serum. Biotechniques. 1997−23:890−892.
- DeMichele A, Martin A.-M., Mick R. et al. Interleukin-6 174G3C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer research. 2003−63:8051−8056.
- Favorov A.V., Andreewski T.V., Sudomoina M.A. et al. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics.2005- 171:2113—2121
- H.M. Чихладзе, Х. Ф. Самедова, M.A. Судомоина и соавторы Сравнительный генетический анализ различных форм низкореццновой артериальной гипертонии. Молекулярная биология.2008:42, 588−598.
- М.Г. Парфенов, Б. В. Титов, М. А. Судомоина, М. Ю и соавторы Комплексный анализ генетической предрасположенности к ишемическому инсульту у русских. Молекулярная биология. 2009−43,937−945.
- Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003−107:363−369.
- Gehring NH, Frede U, Neu-Yilik G et. al Increased efficiency of mRJSTA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia, Nat Genet. 2001−28:389−392.
- Kikuchi M, Hishida A, Ishikawa К et al. Associations between serum C-reactive protein (CRP) levels and polymorphisms of CRP, interleukin IB, and tumor necrosis factor genes among Japanese health checkup examinees. Asian Рас J Cancer Prev 2007−8:87−92
- Barbaux, S, Tregouet DA, Nicaud V et al. Polymorphisms in 33 inflammatory genes and risk of myocardial, infarction—a system genetics approach. J .yj0j, Med.2007−85:1271−1280.
- Licastro F, Chiapelli’M, Caldarera CM et al. Acute myocardial infarction andiproinflammatory gene variants. Ann N Y Acad Sci. 2007- 1119:227−242.
- Bis JC, Heckbert SR, Smith NL et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke Atherosclerosis. 2008- 198:166−173.
- Malarstig A, Wallentin L, Siegbahn A. Genetic variation in the mterleukin-6 gene in relation to risk and outcomes in acute coronary syndrome. Tromb Res 2007−119(4):467−473. Epub 2006 jun 16.